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Mycobacterium xenopi is a nontuberculous mycobacterium
(NTM) that rarely causes pulmonary disease in Asia. Here we
describe the first case of M. xenopi pulmonary disease in Korea.
A 66-year-old man was admitted to our hospital with a 2-month
history of productive cough and hemoptysis. His past medical
history included pulmonary tuberculosis 44 years earlier,
leading to a right upper lobectomy. Chest X-ray upon admission
revealed cavitary consolidation involving the entire right lung.
Numerous acid-fast bacilli were seen in his initial sputum, and
M. xenopi was subsequently identified in more than five sputum
cultures, using molecular methods. Despite treatment with
clarithromycin, rifampicin, ethambutol, and streptomycin, the
infiltrative shadow revealed on chest X-ray increased in size.
The patient's condition worsened, and a right completion
pneumonectomy was performed. The patient consequently died
of respiratory failure on postoperative day 47, secondary to the
development of a late bronchopleural fistula. This case serves
as a reminder to clinicians that the incidence of NTM infection
is increasing in Korea and that unusual NTM are capable of
causing disease in non-immunocompromised patients.
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INTRODUCTION
Nontuberculous mycobacteria (NTM) are ubiq-
uitous organisms, increasingly recognized as an
important cause of chronic pulmonary infection in
non-immunocompromised individuals.
1 Among
NTM, the Mycobacterium avium complex (MAC)
and M. abscessus constitute the most commonly
encountered agents of NTM lung disease in
Korea.
2-4
Mycobacterium xenopi is a slow-growing NTM.
The prevalence of M. xenopi varies geographically;





contrast, it is less commonly identified in the U.
S.
1 M. xenopi is a very rare pathogen of pulmonary
disease in Asia. Until recently, only eight cases of
M. xenopi pulmonary disease have been reported
in Japan.
8
Here, we describe a case of M. xenopi pulmo-
nary disease, the first reported in Korea. The
isolates were identified, using both conventional
microbiological methods and heat-shock protein
65 gene (hsp65) sequence analysis.
CASE REPORT
A 66-year-old man with no history of smoking
was referred to our hospital for further examina-
tion and management of probable NTM lung
disease. His history was significant for pulmonary
tuberculosis 44 years earlier, for which he un-
derwent right upper lobectomy to palliate recur-
rent hemoptysis.
Two months before admission to our hospital,
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the patient reported a 2-month history of produc-
tive cough, hemoptysis, and mild fever. He also
experienced 10 kg weight loss, associated with a
poor appetite. Chest X-ray demonstrated cavitary
consolidation in the right lung, and an acid-fast
bacilli (AFB) stain was positive in his sputum (2+).
The patient was initially diagnosed with pul-
monary tuberculosis and received isoniazid,
rifampicin, ethambutol, and pyrazinamide. After
two months of anti-tuberculous treatment, during
which the patient failed to improve clinically, he
was transferred to our hospital.
Physical examination upon presentation showed
that the patient was 172 cm tall and weighed 54
kg. Vitals included a body temperature of 37.5℃
and a respiratory rate of 20 breaths/min. Coarse
crackles over the right hemithorax were revealed
upon auscultation. No lymphadenopathy was
appreciated.
Laboratory tests revealed a white blood cell
count of 10,520/ L, with a differential of 84.7% μ
neutrophils. The erythrocyte sedimentation rate
was 120 mm/h, and the level of C-reactive protein
was elevated at 16.55 mg/dL. Total proteins were
7.0 g/dL, with a low albumin level (2.3 g/dL). A
human immunodeficiency virus antibody test was
negative.
Chest radiograph revealed a huge cavitary
consolidation involving the entire right lung (Fig.
1A). Significant AFBs were visualized in multiple
sputum specimens; however, repeated nucleic
acid amplification tests for M. tuberculosis, using a
commercial DNA probe (Gen-Probe Amplified
Mycobacterium Tuberculosis Direct Test; Gen-
Probe Inc, San Diego, CA, USA) were negative.
Combination chemotherapy, which included
clarithromycin (1000 mg/day), rifampicin (600 mg/
day), ethambutol (800 mg/day), and streptomycin
(750 mg intramuscular injection three times per
week), was initiated under the tentative diagnosis
of MAC disease.
Subsequently, more than five isolates of myco-
bacteria, obtained from sputum specimens at both
hospitals, were transferred to the Korean Institute
of Tuberculosis and Department of Microbiology
and Immunology at the College of Medicine of
Seoul National University. Species isolation was
performed, using both conventional microbio-
logical and molecular methods.
9,10 All isolates
were identified as M. xenopi, based on heat-shock
protein 65 gene (hsp65) sequence analysis, showing
100% sequence similarity with the M. xenopi
reference strains (Fig. 2). Other mycobacteria were
not isolated along with M. xenopi. The isolates
from this patient were sensitive to isoniazid (0.2
g/mL), rifampicin (40 μ g/mL), streptomycin (4 μ g/ μ
mL), and kanamycin (40 g/mL); but were resistant μ
to ethambutol (2.0 g/mL) on Lowenstein-Jensen μ
media. The isolates were also susceptible to
clarithromycin (16 g/mL), rifabutin (2 μ g/mL), μ
amikacin (16 g/mL), and moxifloxacin (1 μ g/mL) μ
in Middlebrook7H9 broth.
Despite four months of antibiotic therapy, the
disease was progressive. The patient suffered
from profound sputum production and hemop-
tysis. A chest X-ray revealed that the size of the
right lung cavitary consolidation had increased,
and a new infiltrative shadow appeared in the left
Fig. 1. A 66-year-old man with
Mycobacterium xenopi pulmonary
disease. (A) The posteroanterior
chest radiograph revealed cavitary
consolidation in the entire right
lung. (B) The follow-up chest radio-
graph, after antibiotic treatment for
four months, showed that the size
of the cavitary consolidation in the
right lung had increased and that a
new infiltrative shadow appeared in
the left lung. A BPulmonary Disease Caused by Mycobacterium xenopi
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lung (Fig. 1B). The patient complained of
decreased hearing, leading to a discontinuation of
streptomycin treatment. In light of disease pro-
gression and the side effects of streptomycin, the
patient was re-admitted to the hospital where-
upon moxifloxacin (400 mg/day) was added to
the treatment. The patient's condition improved
slightly; however, he eventually underwent right
completion pneumonectomy. Pathology specimens
revealed a near-totally destroyed lung and severe
necrotizing granulomatous inflammation with
caseating necrosis. Postoperatively, gradual im-
provements of the clinical features and radiologic
findings were observed, and a negative con-
version of sputum examinations was achieved.
However, a late bronchopleural fistula developed
acutely 47 days postoperatively, and the patient
subsequently expired with pneumonia and respi-
ratory failure.
DISCUSSION
To the best of our knowledge, this is the first
case of pulmonary disease caused by Mycobacterium
xenopi in Korea. M. xenopi was clearly shown to
be the etiologic agent of the cavitary consoli-
dative changes in our case. Considering clinical
and radiographic features, in addition to
repeated isolation of M. xenopi, the diagnostic
criteria for NTM pulmonary disease were
fulfilled.
1
M. xenopi is a ubiquitous, thermophilic, slow-
growing NTM. This organism is found in fresh-
water and has been isolated from water samples
collected in homes and hospitals.
1 M. xenopi
appears to have a variable geographic distribu-
tion. It has been recovered frequently from clinical
specimens in the United Kingdom, northwestern
Europe, and Canada; rarely has it been isolated in
the U. S. prior to the AIDS epidemic.
11 M. xenopi
is a very rare pathogen of pulmonary disease in
Asian countries, including Japan and Korea.
Recently, we reported the clinical significance of
NTM isolates from respiratory specimens in
Korea.
4 In that study, only one of more than 1,500
isolates of NTM from about 800 patients was
confirmed to be M. xenopi, and its clinical signifi-
cance was doubtful.
However, M. xenopi is increasingly recognized
as a cause of pulmonary infection. Clinical illness
typically presents as an indolent, cavitary lung
infection in middle-aged men. Most of those
patients have a history of underlying chronic
pulmonary disease.
1 Conditions predisposing an
individual to M. xenopi infection include previ-
ously treated pulmonary tuberculosis, chronic
obstructive pulmonary disease, diabetes mellitus,
alcoholism, and a bad postoperative state.
5-7,12,13
The classic radiographic appearance of M. xenopi
pulmonary disease is a cavitary, apical pulmonary
process.
5-7,12-14
The optimal therapy and duration of treatment
for pulmonary disease secondary to M. xenopi
has not been established. Current protocols for
M. xenopi infection recommend chemotherapeutic
combination with three or four drugs and an
overall treatment duration of 18-24 months.
1,7,15
The in vitro susceptibility to anti-tuberculosis
agents is variable, although enhanced drug
Fig. 2. Species identification of strain S1 in this study
based on a comparative analysis of partial hsp65 sequences
(422 bp). The tree was constructed from all 56
mycobacteria reference strains and strain S1, using the
neighbor-joining method. The percentages indicated at
nodes represent bootstrap levels supported by 1,000
re-sampled datasets. Bootstrap values < 50% are not
shown.Hye Yun Park, et al.
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activity has been demonstrated with the combi-
nation of rifampicin and streptomycin, or
rifampicin and ethambutol.
16 There was no
correlation between treatment outcome and in
vitro susceptibility.
5 The cornerstone of treatment
for M. xenopi infection is currently a combination
of rifampicin and ethambutol. Although about
70% of clinical isolates of M. xenopi are resistant
to ethambutol, ethambutol is strongly recom-
mended.
5 A prospective, randomized study
found that the addition of isoniazid is of little or
no value in the treatment of M. xenopi infection.
5
Some studies of clarithromycin-containing
regimens demonstrated good bactericidal
activity.
17,18 In addition, the successful treatment
of M. xenopi infection with a combination of
clarithromycin and newer quinolones has also
been described.
19
The death rate of pulmonary disease secondary
to M. xenopi is as high as 70% within five years
of onset.
5 Although underlying comorbidities
might be a major factor determining the death
rate, the poor response to antibiotic treatment is
alarming. Given the relative ineffectiveness of
medical therapy, surgery is an important
alternative in patient who can tolerate it.
20 Although
some investigators have reported success with
surgical therapy, others have had disappointing
results.
6,13
Based on recommended treatment regimens
and the results of in vitro susceptibility testing, we
initially selected a combination of clarithromycin,
rifampicin, ethambutol, and streptomycin for our
patient. After four months of antibiotic therapy,
moxifloxacin was added due to adverse effects
with streptomycin and disease progression.
Finally, pulmonary resection was performed.
Unfortunately, the patient expired because a
bronchopleural fistula developed and led to
pneumonia and respiratory failure.
In conclusion, Mycobacterium xenopi is considered
to be a cause of pulmonary infection in immu-
nocompetent patients with pre-existing lung
disease. This case serves as a reminder to
clinicians that the incidence of NTM infection is
increasing in Korea, and that unusual NTM
organisms are capable of causing disease in non-
immunocompromised patients.
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